- Home
- MRNO vs ABUS Comparison
MRNO vs ABUS Comparison
Compare MRNO & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRNO
- ABUS
- Stock Information
- Founded
- MRNO 2021
- ABUS 2005
- Country
- MRNO United Kingdom
- ABUS United States
- Employees
- MRNO N/A
- ABUS N/A
- Industry
- MRNO
- ABUS Biotechnology: Pharmaceutical Preparations
- Sector
- MRNO
- ABUS Health Care
- Exchange
- MRNO NYSE
- ABUS Nasdaq
- Market Cap
- MRNO 739.2M
- ABUS 611.0M
- IPO Year
- MRNO N/A
- ABUS N/A
- Fundamental
- Price
- MRNO $7.92
- ABUS $3.22
- Analyst Decision
- MRNO
- ABUS Strong Buy
- Analyst Count
- MRNO 0
- ABUS 4
- Target Price
- MRNO N/A
- ABUS $5.50
- AVG Volume (30 Days)
- MRNO 27.1K
- ABUS 766.0K
- Earning Date
- MRNO 08-25-2025
- ABUS 08-04-2025
- Dividend Yield
- MRNO N/A
- ABUS N/A
- EPS Growth
- MRNO N/A
- ABUS N/A
- EPS
- MRNO N/A
- ABUS N/A
- Revenue
- MRNO $46,166,185.00
- ABUS $6,403,000.00
- Revenue This Year
- MRNO N/A
- ABUS $3.35
- Revenue Next Year
- MRNO N/A
- ABUS N/A
- P/E Ratio
- MRNO N/A
- ABUS N/A
- Revenue Growth
- MRNO 169.39
- ABUS N/A
- 52 Week Low
- MRNO $5.70
- ABUS $2.71
- 52 Week High
- MRNO $13.25
- ABUS $4.73
- Technical
- Relative Strength Index (RSI)
- MRNO 39.64
- ABUS 48.90
- Support Level
- MRNO $6.77
- ABUS $3.08
- Resistance Level
- MRNO $8.50
- ABUS $3.30
- Average True Range (ATR)
- MRNO 0.89
- ABUS 0.10
- MACD
- MRNO -0.07
- ABUS 0.01
- Stochastic Oscillator
- MRNO 26.93
- ABUS 50.00
About MRNO MURANO GLOBAL INVESTMENTS LIMITED
Murano Global Investments PLC is a real estate company that owns, develops, and invests in hotel, resort, and commercial properties throughout Mexico. Its portfolio includes the Andaz and Mondrian Hotels in Mexico City and Vivid Hotel Grand Island. The revenues are derived from the products and services provided to customers such as Room rentals, Food and beverage, Private events, Spa services, and Other services.
About ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.